Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Yoichiro Kino"'
Autor:
Fumihito Muro, Tomoyoshi Sobue, Yasushi Itoh, Yuya Mori, Naoki Nomura, Yoichiro Kino, Chimuka Handabile, Hiroki Kitayama, Ryotarou Mitsumata, Hironori Hatanaka, Kazuhiko Kimachi, Ryosuke Omori, Tomohiro Nishimura, Misako Nakayama, Kazumasa Ogasawara, Brendon Y. Chua, Cong Thanh Nguyen, Marumi Ohno, David C. Jackson, Katherine Kedzierska, Masafumi Endo, Toshiki Sekiya, Marios Koutsakos, Yuki Ohara, Saori Suzuki, Masashi Shingai, Lorena E. Brown, Tomio Ikeda, Daisuke Fujikura, Hirohito Ishigaki, Hiroshi Kida
Publikováno v:
Vaccine. 39(29):3940-3951
Current detergent or ether-disrupted split vaccines (SVs) for influenza do not always induce adequate immune responses, especially in young children. This contrasts with the whole virus particle vaccines (WPVs) originally used against influenza that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88895542299a3f804ba6afb5ab665b89
http://hdl.handle.net/2115/86168
http://hdl.handle.net/2115/86168
Publikováno v:
The Journal of Infectious Diseases. 224:1446-1448
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b30f095ffb160c508df33739d030b041
https://doi.org/10.1093/infdis/jiab028
https://doi.org/10.1093/infdis/jiab028
Autor:
Masafumi Endo, Takeshi Naruse, Tetsuro Tanabe, Kohji Ueda, Tadashi Fukuda, Mitsuyoshi Tanishima, Kayo Ibaragi, Kenshi Hayashida, Yoichiro Kino
Publikováno v:
Influenza and Other Respiratory Viruses. 14:551-563
Background We have developed an AS03-adjuvanted H5N1 influenza vaccine produced in an EB66® cell culture platform (KD-295). Objectives In accordance with Japanese guidelines for development of pandemic prototype vaccines, the phase II study was cond
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5a3b99b3dba1d5fc2b206f19391b9d2
https://doi.org/10.1111/irv.12755
https://doi.org/10.1111/irv.12755
Autor:
Marumi Ohno, Masataka Sagata, Toshiki Sekiya, Naoki Nomura, Masashi Shingai, Masafumi Endo, Kazuhiko Kimachi, Saori Suzuki, Cong Thanh Nguyen, Misako Nakayama, Hirohito Ishigaki, Kazumasa Ogasawara, Yasushi Itoh, Yoichiro Kino, Hiroshi Kida
Publikováno v:
Vaccine. 41(3)
Among inactivated influenza vaccines, the whole virus particle vaccine (WPV) elicits superior priming responses to split virus vaccine (SV) in efficiently inducing humoral and cellular immunity. However, there is concern for undesired adverse events
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3af0dae08f261feab26ac28ffb98b5d
https://pubmed.ncbi.nlm.nih.gov/36526501
https://pubmed.ncbi.nlm.nih.gov/36526501
Autor:
Mayumi Sasada, Hironori Hatanaka, Marumi Ohno, Lorena E. Brown, Hiroshi Kida, Yuki Ohara, Daisuke Fujikura, Hiroki Kitayama, Masafumi Endo, Naoki Nomura, Tomio Ikeda, Masashi Shingai, Tomohiro Nishimura, Kazumasa Ogasawara, Tomoyoshi Sobue, Kenji Motokawa, Yoichiro Kino, Takuji Daito, Edin J Mifsud, Saori Suzuki, Yasushi Itoh, Ryotarou Mitsumata, Toshiki Sekiya
Publikováno v:
Vaccine. 37:2158-2166
In contrast to current ether- or detergent-disrupted "split" vaccines (SVs) for influenza, inactivated whole influenza virus particle vaccines (WPVs) retain the original virus structure and components and as such may confer similar immunity to natura
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4c81049c83b595e3093f645381468e6
https://doi.org/10.1016/j.vaccine.2019.02.057
https://doi.org/10.1016/j.vaccine.2019.02.057
Autor:
Marios Koutsakos, Tomohiro Nishimura, Cong Thanh Nguyen, Hiroshi Kida, Misako Nakayama, Masafumi Endo, Kazumasa Ogasawara, Katherine Kedzierska, Brendon Yew Loong Chua, Thi H. O. Nguyen, Marumi Ohno, David C. Jackson, Yasushi Itoh, Lorena E Brown, Jennifer A Juno, Masashi Shingai, Adam K. Wheatley, Naoki Nomura, Hirohito Ishigaki, Yoichiro Kino, Toshiki Sekiya, Saori Suzuki, Stephen J. Kent, Yuki Ohara
Publikováno v:
Immunology and cell biologyReferences. 99(1)
Influenza remains a significant global public health burden, despite substantial annual vaccination efforts against circulating virus strains. As a result, novel vaccine approaches are needed to generate long-lasting and universal broadly cross-react
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c06577b62477b7736d2a7bc1538f04f4
https://pubmed.ncbi.nlm.nih.gov/32741011
https://pubmed.ncbi.nlm.nih.gov/32741011
Publikováno v:
Vaccine. 34:4079-4082
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8156f23580d0d84fbc4cf915e30687db
https://doi.org/10.1016/j.vaccine.2016.06.030
https://doi.org/10.1016/j.vaccine.2016.06.030
Publikováno v:
Journal of Allergy and Clinical Immunology. 137(3):861-867
Background Influenza vaccines produced in embryonated eggs might pose a risk to patients with egg allergy. However, patients experiencing influenza vaccine–associated anaphylaxis (IVA) do not always have egg allergy. In the 2011-2012 season, an unu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db0e41fc44244eda92e0ec9617f6d3cf
Autor:
Masafumi, Endo, Mitsuyoshi, Tanishima, Kayo, Ibaragi, Kenshi, Hayashida, Tadashi, Fukuda, Tetsuro, Tanabe, Takeshi, Naruse, Yoichiro, Kino, Kohji, Ueda
Publikováno v:
Influenza and Other Respiratory Viruses
Background We have developed an AS03‐adjuvanted H5N1 influenza vaccine produced in an EB66® cell culture platform (KD‐295). Objectives In accordance with Japanese guidelines for development of pandemic prototype vaccines, the phase II study was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::19789a22c30f1519768c0c8c8047dc3e
https://pubmed.ncbi.nlm.nih.gov/32579785
https://pubmed.ncbi.nlm.nih.gov/32579785
Autor:
Kazuhiko Kimachi, Takeshi Naruse, Munetaka Ichikawa, Shinji Tochihara, Tetsuro Tanabe, Kohji Ueda, Yoichiro Kino, Yoshiaki Oda, Tadashi Fukuda
Publikováno v:
Vaccine. 33:6078-6084
Background We conducted a phase I clinical trial of a cell culture-derived AS03-adjuvanted influenza vaccine containing HA antigen (A/Indonesia/05/2005(H5N1)/PR8-IBCDC-RG2) derived from EB66 cells (KD-295). Methods Healthy male adult volunteers (20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a0dc6e8fa7a2739d54cfda8041437e1
https://doi.org/10.1016/j.vaccine.2015.09.022
https://doi.org/10.1016/j.vaccine.2015.09.022